Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI109722

Stereoselective Interaction of Phenylbutazone with [12C/13C]Warfarin Pseudoracemates in Man

Robert A. O'Reilly, William F. Trager, Catherine H. Motley, and William Howald

Departments of Medicine, Santa Clara Valley Medical Center, San Jose, California 94143

University of California, San Francisco, San Francisco, California 94143

Institute for Medical Research of Santa Clara County, San Jose, California 95128

Department of Pharmaceutical Science, University of Washington, Seattle, Washington 58195

Find articles by O'Reilly, R. in: JCI | PubMed | Google Scholar

Departments of Medicine, Santa Clara Valley Medical Center, San Jose, California 94143

University of California, San Francisco, San Francisco, California 94143

Institute for Medical Research of Santa Clara County, San Jose, California 95128

Department of Pharmaceutical Science, University of Washington, Seattle, Washington 58195

Find articles by Trager, W. in: JCI | PubMed | Google Scholar

Departments of Medicine, Santa Clara Valley Medical Center, San Jose, California 94143

University of California, San Francisco, San Francisco, California 94143

Institute for Medical Research of Santa Clara County, San Jose, California 95128

Department of Pharmaceutical Science, University of Washington, Seattle, Washington 58195

Find articles by Motley, C. in: JCI | PubMed | Google Scholar

Departments of Medicine, Santa Clara Valley Medical Center, San Jose, California 94143

University of California, San Francisco, San Francisco, California 94143

Institute for Medical Research of Santa Clara County, San Jose, California 95128

Department of Pharmaceutical Science, University of Washington, Seattle, Washington 58195

Find articles by Howald, W. in: JCI | PubMed | Google Scholar

Published March 1, 1980 - More info

Published in Volume 65, Issue 3 on March 1, 1980
J Clin Invest. 1980;65(3):746–753. https://doi.org/10.1172/JCI109722.
© 1980 The American Society for Clinical Investigation
Published March 1, 1980 - Version history
View PDF
Abstract

To evaluate the interaction of phenylbutazone with racemic warfarin or R,S-(±)-warfarin in man, S-(−)-warfarin or levowarfarin was synthesized with 13C label in the 2-position of the coumarin nucleus and added to [12C]R(+)-warfarin or dextrowarfarin to form a [12C/13C]pseudoracemate of warfarin. In six normal human subjects, a single oral dose of this “cold labeled” pseudoracemate, 1.5 mg/kg body weight, was administered with and without a daily dosage of phenylbutazone, 300 mg orally, beginning 3 d before the warfarin dose and continuing throughout the hypoprothrombinemia. Plasma samples were obtained daily and analyzed for warfarin content and for one-stage prothrombin activity. Unchanged warfarin in the plasma was fractionated by normal-phase, high-pressure liquid chromatography, and the enantiomorphic ratios were determined by chemical-ionization mass spectrometry with pentadeuteriowarfarin as the internal standard. A highly significant augmentation of the hypoprothrombinemia of the pseudoracemate occurred during the phenylbutazone regimen (P < 0.001) compared with pseudoracemic warfarin administered alone. There was a highly significant increase in the plasma clearance of dextrowarfarin (P < 0.01) and a significant decrease in the plasma clearance of levowarfarin (P < 0.05) during the phenylbutazone regimen compared with administration of warfarin alone. It was concluded that phenylbutazone augmented the hypoprothrombinemia of pseudoracemic warfarin stereoselectively by inhibiting the metabolic disposition of the more hypoprothrombinemic levowarfarin, yet reduced the plasma levels of pseudoracemic warfarin by greatly augmenting the metabolic disposition of dextrowarfarin.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 746
page 746
icon of scanned page 747
page 747
icon of scanned page 748
page 748
icon of scanned page 749
page 749
icon of scanned page 750
page 750
icon of scanned page 751
page 751
icon of scanned page 752
page 752
icon of scanned page 753
page 753
Version history
  • Version 1 (March 1, 1980): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts